In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.

Regeneron Pharmaceuticals ... Analysts project that Eylea’s sales will face continued pressure, potentially leading to a substantial decline in market share. The slower-than-expected switch ...

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Much of this decline can be attributed to the company’s weaker-than-expected performance, particularly concerning its existing blockbuster treatment, Eylea. Adding to Regeneron’s woes ...

We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest’s Substack. In ...

Regeneron anticipates a decline in EYLEA sales due to biosimilar competition. DUPIXENT continues to expand globally, with significant growth expected by 2030. The company is investing $7 billion ...

Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered ...

Regeneron Pharmaceuticals Inc. (NASDAQ ... Analysts project that Eylea’s sales will face continued pressure, potentially leading to a substantial decline in market share. The slower-than-expected ...

resulting in a notable decline in EYLEA sales. Management also discussed the impact of lower inventory levels and persistent competitive pressures across key products. Looking forward, Regeneron ...

resulting in a notable decline in EYLEA sales. Management also discussed the impact of lower inventory levels and persistent competitive pressures across key products. Looking forward, Regeneron’s ...